Anti-VEGF drugs, in particular bevacizumab, have shown promising activity as single agents in chemotherapy-resistant ovarian cancer, supporting the strong pre-clinical rationale for the utility of this treatment strategy. Here, VEGFA is linked to ovarian cancer.